Skip to content

2026

Posts are organized into categories for ease of navigation:

Database release

This release covers the 41 pull requests merged between 2026-05-08 and 2026-10-29, and is a formal launch of a 2.0.0 state of moalmanac-db. It adds 60 indications: 9 from FDA, 22 from EMA, 14 from Health Canada (HC), and 15 from the Health Service Executive (HSE). Over the same period, the relational database in referenced/ was rebuilt to align more closely with GA4GH VA-Spec, VRS, and Cat-VRS, and the database content is now licensed under CC BY 4.0.

View on GitHub

Database release

This Release contains updates to the draft version of the database. Concept mappings to RxNorm, SNOMED, and OMOP are now present for all curated therapies. We additionally curate an approval for imlunestrant from the European Medicines Agency, as well as another for belzutifan from both the European Medicines Agency and Food and Drug Administration.

View on GitHub

Database release

This release contains updates to the draft version of the database. EGFR TKD activating variants was introduced as a biomarker and associated with regulatory approvals from the European Medicines Agency (EMA) and Health Canada (HC). No additional genomic knowledge statements were added with this release, though several were modified.

Database release

This release contains updates to the draft version of the database with FDA precision oncology approvals from February 2026. Specifically, indications and derived relationships were updated for Braftovi (encorafenib), Hernexeos (zongertinib), and Keytruda (pembrolizumab).

Database release

This release contains updates to the draft version of the database with FDA precision oncology approvals for Akeega. Additionally, the Organizations table was merged into the Agents table.